EMA Sees Rise in Trial Applications Submitted to CTIS
The European Medicines Agency (EMA) has seen a modest but steady rise in the number of trial applications submitted to its new Clinical Trial Information System (CTIS) since the platform launched on Jan. 31.
Although most trial applications are still being filed to the EudraCT system, which stakeholders may continue using until Jan. 31, 2023, a recent EMA report shows that the number of applications filed to CTIS has risen month over month, starting with nine applications in February and rising to 18 in March, 29 in April, 35 in May and 39 in June. May and June each also saw one substantial modification submission.
By contrast, EudraCT application numbers are beginning to dip slightly; the system saw 193 applications in February, 200 in March, 187 in April, 178 in May and 175 in June.
So far, the agency has made 24 decisions on trial applications filed to CTIS, picking up speed as the year went on. It made just a single one in March, three in April and four in May, but shot up to 16 in June.
Read the full report here: https://bit.ly/3QiM3L9.